Search - tctmd.com

Displaying 61 - 80 of 102

Sort: Relevancy | Date

Presentation TCT 2017

Poland Comments: How Would I Treat This Case?

Presenter: Dariusz Dudek, Martin Hudec, Wojtek Wojakowski

October 30, 2017

Presentation TCT 2017

Czech Republic Presents: Case Introduction - Severe Aortic Stenosis in a Low-Risk Patient

Presenter: Dariusz Dudek, Martin Hudec, Marian Branny

October 30, 2017

Presentation TCT 2017

Germany Presents: Future Perspective - TAVR Compared to Surgical Valve Replacement in Patients With Low-Risk Scores Potential Benefits and Harms

Presenter: Dariusz Dudek, Martin Hudec, Michael Haude

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing LOW RISK TAVR Trials Change How We Treat Low Surgical Risk Patients With Aortic Stenosis?

Presenter: David H. Adams, Ted Feldman, Craig R. Smith

October 30, 2017

Presentation TCT 2017

Were ready to treat bicuspid valve and lower-risk tricuspid valve aortic stenosis!

Presenter: Susheel K. Kodali

October 30, 2017

Presentation TCT 2017

TAVR in Low-Risk Patients

Presenter: Jeroen J. Bax, Axel Linke, Thomas Pilgrim

October 29, 2017

Presentation TVT 2017

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation SIF 2017

TAVR Will Be Default in Low Risk Patients

Presenter: David L. Brown

March 11, 2017

Presentation TCT 2016

FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways

Presenter: Nicole Ibrahim, Martin B. Leon, Jaime Raben

November 01, 2016

Presentation TCT 2016

Debate - Should TAVR Be Offered to Every Patient With Aortic Stenosis? No, Given All the Uncertainties About Durability, Valve Thrombus, etc. - Wait for the Data in Low-risk Patients!

Presenter: Andreas Baumbach, David Hildick-Smith, Wilson Y. Szeto

November 01, 2016

Presentation TCT 2016

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Presenter: Raj Makkar, Lars Sondergaard, Stephen J.D. Brecker

October 31, 2016

Presentation TCT 2016

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

Presenter: Raj Makkar, Lars Sondergaard, Antonio Colombo

October 31, 2016

Presentation TCT 2016

TAVR for Intermediate-Risk and Low-Risk Patients: Review of the Literature

Presenter: Niall T. Mulvihill, Michael Mahmoudi

October 31, 2016

Presentation TCT 2016

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Con Position

Presenter: Niall T. Mulvihill, Hellmuth Weich

October 31, 2016

Presentation TCT 2016

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Pro Position

Presenter: Niall T. Mulvihill, Antoniette Neylon

October 31, 2016

Presentation TCT 2016

Introduction: TAVR in Intermediate-Risk and Low-Risk With Severe Aortic Stenosis

Presenter: Niall T. Mulvihill

October 31, 2016

Presentation TCT 2016

Debate: TAVR for Low Risk Patients Is It time? NO, We Dont Yet Know if Its as Durable as Surgical AVR!

Presenter: Russell A. Brandwein, Isaac George

October 30, 2016

Presentation TCT 2016

Debate: TAVR for Low Risk Patients Is It time? YES, the Data Is Sufficient and Our Patients Want It!

Presenter: Russell A. Brandwein, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint Stay the Course: We Need the Next Round of Low-Risk Randomized TAVR Studies AND Long-Term Follow-up to Justify Changes!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Lars G. Svensson

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Advertisement

Poland Comments: How Would I Treat This Case?

Czech Republic Presents: Case Introduction - Severe Aortic Stenosis in a Low-Risk Patient

Germany Presents: Future Perspective - TAVR Compared to Surgical Valve Replacement in Patients With Low-Risk Scores Potential Benefits and Harms

Predicting the Future: Will the Ongoing LOW RISK TAVR Trials Change How We Treat Low Surgical Risk Patients With Aortic Stenosis?

Were ready to treat bicuspid valve and lower-risk tricuspid valve aortic stenosis!

TAVR in Low-Risk Patients

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

TAVR Will Be Default in Low Risk Patients

FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways

Debate - Should TAVR Be Offered to Every Patient With Aortic Stenosis? No, Given All the Uncertainties About Durability, Valve Thrombus, etc. - Wait for the Data in Low-risk Patients!

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

TAVR for Intermediate-Risk and Low-Risk Patients: Review of the Literature

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Con Position

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Pro Position

Introduction: TAVR in Intermediate-Risk and Low-Risk With Severe Aortic Stenosis

Debate: TAVR for Low Risk Patients Is It time? NO, We Dont Yet Know if Its as Durable as Surgical AVR!

Debate: TAVR for Low Risk Patients Is It time? YES, the Data Is Sufficient and Our Patients Want It!

Flash Debate: Counterpoint Stay the Course: We Need the Next Round of Low-Risk Randomized TAVR Studies AND Long-Term Follow-up to Justify Changes!

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content